Efavirenz (Sustiva®) is a first-generation non-nucleoside reverse transcriptase inhibitor
(NNRTI) used to treat human immunodeficiency virus (HIV) type 1 infection or to prevent the …

Therapeutic research and development for Alzheimer's disease (AD) has been an area of
intense research to alleviate memory loss and neurodegeneration. There is growing interest …

Background: Medicinal products that have been developed and approved for one disease
may be the object of additional clinical development in other disease areas or of additional …

The resistance of Plasmodium falciparum, the causative agent of malaria, against quinine
and chloroquine along with the lack of malaria vaccines has encouraged the development of …

In this paper, we study the competitive effects of bundled discounts offered by pairs of
independent firms. In a setting with vertically differentiated goods, where firms decide …

Cenicriviroc mesylate (CVC) is a potent dual antagonist of CC chemokine receptor type 5
(CCR5) and CC chemokine receptor type 2 (CCR2) in phase 2b development as an entry …

Resumen VELVANATHAN, Tineshwaran; ISLAHUDIN, Farida; SIM, Benedict L. y TAHA, Nur
A.. Simplification of HAART therapy on ambulatory HIV patients in Malaysia: a randomized …

AIM To investigate the mechanism (s) by which potential effects of multi-drug highly-active
antiretroviral therapy contributes to lipodystrophy syndrome. METHODS Preadipocytes from …

Feline infectious peritonitis (FIP), caused by a genetic mutant of feline enteric coronavirus
known as FIPV, is a highly fatal disease of cats with no currently available vaccine or FDA …

HIV pre-exposure prophylaxis (PrEP) with emtricitabine (FTC) and tenofovir disoproxil
fumarate (TDF) fixed-dose combination (FTC/TDF) is undergoing rapid scale-up in the …